ARTEMIDE-Gastric01: a phase 3 randomized study of rilvegostomig with fluoropyrimidine and trastuzumab deruxtecan (T-DXd) as first-line (1L) treatment for locally advanced or metastatic HER2-positive gastric or gastroesophageal junction cancer (GC/GEJC)

oxaliplatin - Generic mfg.

Enhertu (fam-trastuzumab deruxtecan-nxki) - Daiichi Sankyo, AstraZeneca

5-fluorouracil - Generic mfg.

rilvegostomig (AZD2936) - AstraZeneca

capecitabine - Generic mfg.

Keytruda (pembrolizumab) - Merck (MSD)

cisplatin - Generic mfg.

https://pag.virtual-meeting.org/KUKM/dkk2026/de-DE/pag/presentation/438094

Jack Chater 1; Rui-Hua Xu 2; Diogo Diniz Gomes Bugano 3; Jen-Shi Chen 4; Florian Lordick 5; Scott Paulson 6; Sun-Young Rha 7; Josep Tabernero 8; Kensei Yamaguchi 9; Jun Zhang 10; Jacqui Aitchison 11; Zhouer Sun 12; Qian Zhu 13; Yellen Xia 13; Anastasiya Jiang 13; Xia Li 14; Osama Rahma 15; Manish A. Shah 16

Feb 10, 2026